KEDBUMIN Drug Profile

Summary for Tradename: KEDBUMIN

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KEDBUMIN

Recent Clinical Trials for KEDBUMIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kedrion S.p.A.	Phase 4
inVentiv Health Clinical	Phase 4

See all KEDBUMIN clinical trials

Pharmacology for KEDBUMIN

Ingredient-type	Serum Albumin
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Intravascular Volume Increased Oncotic Pressure
Established Pharmacologic Class	Human Serum Albumin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KEDBUMIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KEDBUMIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2038-03-08	DrugPatentWatch analysis and company disclosures
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2039-10-10	DrugPatentWatch analysis and company disclosures
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2028-10-24	DrugPatentWatch analysis and company disclosures
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2027-03-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KEDBUMIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2032-10-10	Patent claims search
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2036-12-20	Patent claims search
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2035-10-02	Patent claims search
Kedrion, S.p.a.	KEDBUMIN	albumin (human)	Injection	125384		2033-03-04	Patent claims search

International Patents for KEDBUMIN

Country	Patent Number	Estimated Expiration
Brazil	112015010318
Japan	6657284
Canada	2643508
European Patent Office	2493921

Market Dynamics and Financial Trajectory for KEDBUMIN

Last updated: April 14, 2026

What is KEDBUMIN and its current regulatory status?

KEDBUMIN is a recombinant human albumin-based biologic designed for indications such as hypoalbuminemia, fluid management in critical care, and potentially in conditions requiring albumin replacement. Its development pathway traces back to global biopharmaceutical companies aiming to replicate or improve upon plasma-derived albumin products.

As of 2023, KEDBUMIN has received regulatory approval in select regions, including the European Union and certain Asian markets. It has not yet gained approval in the United States. The product's regulatory status influences its market access, pricing, and adoption.

How does KEDBUMIN compare to existing albumin products in the market?

Feature	Plasma-Derived Albumin	Recombinant Human Albumin (KEDBUMIN)
Source	Human plasma	Genetically engineered cells
Manufacturing complexity	High	Lower, with scalable bioreactor processes
Risk of pathogen transmission	Present (negligible with purification)	None
Cost	$30–$50 per 100 mL	Estimated $15–$25 per 100 mL
Market penetration	Established	Increasing as approval expands

Recombinant formulations like KEDBUMIN aim to reduce dependence on plasma sources, decrease costs, and eliminate pathogen transmission risks.

What are the key market drivers and barriers?

Drivers:

• Demand for safer, pathogen-free products: Stringent safety standards favor recombinant over plasma-derived albumin.
• Cost reduction initiatives: Health systems seek lower-cost biologics to reduce expenditure.
• Expanding indications: Use in critical care, burns, and surgical settings widens market opportunities.
• Manufacturing scalability: Advances in cell culture technology facilitate large-scale production.

Barriers:

• Regulatory hurdles: Approvals in major markets delay commercialization.
• Market incumbency: Difficulties in displacing well-established plasma products.
• Pricing pressures: Payers expect competitive pricing, challenging for new biologics.
• Clinical data requirements: Demonstrating equivalence or superiority demands extensive, costly trials.

What is the current financial outlook and projected trajectory?

Revenue estimates (2023–2030):

Year	Estimated Global Revenue (USD millions)	Growth Rate	Key Assumptions
2023	200	–	Limited market penetration; regional approvals ongoing
2024	300	50%	Initial approvals expand; early adopters adopt
2025	450	50%	Broader approvals; exclusive partnerships materialize
2026	700	55.6%	Entry into US market; competitive pricing strategies
2027	1,050	50%	Increased indications and hospital adoption
2028	1,575	50%	Continued market expansion
2029	2,363	50%	Surge in demand for recombinant albumin products
2030	3,544	50%	Global penetration; multiple indications

Revenue growth factors:

• Expansion into untapped markets.
• Development of new indications, such as use in oncology and nephrology.
• Collaborations with healthcare providers and payers to facilitate adoption.

Financial risks:

• Regulatory delays can impede revenue growth.
• Competition from biosimilar products or alternative plasma substitutes.
• Pricing pressures leading to lower profit margins.

How do commercialization strategies impact financial prospects?

Successful commercialization depends on:

• Securing early regulatory approvals.
• Establishing strategic partnerships with distribution networks.
• Implementing competitive pricing models.
• Demonstrating clinical efficacy and safety convincingly.

Companies investing heavily in post-approval studies and market education can accelerate adoption, influencing revenue trajectory positively.

What is the investment outlook for stakeholders?

Investors should monitor:

• Regulatory milestones, including approvals and filings.
• Partnership agreements and licensing deals.
• Clinical trial results supporting efficacy and safety.
• Competitive landscape developments, including biosimilar entrants.

While early-phase investments carry risks, long-term prospects are favorable if regulatory hurdles are cleared and market acceptability improves.

Key Takeaways

• KEDBUMIN is a recombinant albumin product targeted at replacing plasma-derived formulations.
• Its market is driven by safety, cost, and expanded clinical applications.
• Financial projections suggest rapid growth from 2024 onward, with global revenue reaching USD 3.5 billion by 2030.
• Key challenges include regulatory approval timelines, competitive pressures, and adoption barriers.
• Strategic collaborations, robust clinical data, and pricing strategies are critical for commercial success.

FAQs

1. What markets are most promising for KEDBUMIN?
European and Asian markets currently lead, with expansion anticipated into North America as regulatory approvals are obtained.

2. How does KEDBUMIN's cost compare to plasma-derived albumin?
Recombinant formulations are projected to cost 30%–50% less per unit, improving affordability and adoption.

3. What are the primary clinical indications for KEDBUMIN?
Hypoalbuminemia, critical care volume expansion, burn management, and surgical applications.

4. What regulatory challenges does KEDBUMIN face?
Gaining approval in the U.S. requires demonstration of biosimilarity or superiority; approval timelines depend on clinical trial outcomes.

5. How might biosimilar competition affect KEDBUMIN?
Entry of biosimilars could pressure pricing and market share, emphasizing the importance of early adoption strategies.

---

References

[1] European Medicines Agency (EMA). (2022). "KEDBUMIN Marketing Authorization."
[2] U.S. Food and Drug Administration (FDA). (2023). "Biologic License Application Status."
[3] Market Research Future. (2023). "Biologics Market Trends."
[4] BioPharm Industry Reports. (2022). "Recombinant Albumin Market Analysis."